Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a leading radiopharmaceutical-focused company, dedicated to the development, manufacture, and commercialization of innovative diagnostic imaging agents and products. Headquartered in North Billerica, Massachusetts, and with additional offices in Puerto Rico and Canada, Lantheus has been a pivotal player in the medical imaging industry for over 65 years.
The company's primary subsidiary, Lantheus Medical Imaging, Inc. (LMI), specializes in diagnostic imaging solutions primarily for cardiovascular diseases. Key products include the echocardiography contrast agent DEFINITY® Vial, the technetium-based generator TechneLite®, and the inhaled radiopharmaceutical imaging agent Xenon Xe 133 Gas for lung imaging.
Lantheus is organized into three main business units: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostics focuses on products that assist healthcare professionals in detecting and monitoring diseases, particularly in cardiology. Radiopharmaceutical Oncology offers diagnostics and therapeutic solutions that help healthcare providers manage cancer. Through its Strategic Partnerships, Lantheus collaborates to advance precision medicine using biomarkers and digital solutions.
Recent achievements include strategic transactions to enhance their pipeline for neuroendocrine tumors and prostate cancer. Lantheus has partnered with Perspective Therapeutics, which has developed a best-in-class alpha therapy platform, enabling Lantheus to expand its pipeline into promising alpha therapies.
Financially, Lantheus has shown robust performance. The company reported record revenues of $1.3 billion for the full year 2023, marking a 38.6% increase from 2022. This growth was driven by the successful commercialization of innovative products and strategic acquisitions.
In the Radiopharmaceutical Oncology space, the company’s Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate has been accepted by the FDA. This product is intended for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Lantheus continues to drive innovation and growth through its robust pipeline and strategic collaborations. Recent leadership changes have positioned the company for its next phase of growth, with Brian Markison taking over as CEO from March 2024, following the successful tenure of Mary Anne Heino.
For ongoing updates and more information, visit their website at www.lantheus.com.
Lantheus Holdings reported a remarkable first quarter of 2022 with worldwide revenue of $208.9 million, a 125.8% increase from the previous year. The company's GAAP net income surged to $43.0 million or $0.61 per share, up from $9.0 million or $0.13 per share in Q1 2021. Adjusted fully diluted EPS rose to $0.97, significantly higher than $0.05 a year prior. The company also provided a Q2 revenue guidance of $200 million - $215 million and updated its full-year revenue guidance to $800 million - $835 million.
Lantheus Holdings (NASDAQ: LNTH) will host a conference call on April 29, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial and operating results. Investors can access the call via telephone or through a live webcast on the company's investor website. A replay will be available two hours post-call for 30 days. Lantheus, based in North Billerica, Massachusetts, specializes in imaging diagnostics and therapeutics, with a diverse product portfolio including DEFINITY®, PYLARIFY®, and RELISTOR®.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced the appointment of Jean-Claude Provost, MD, as Interim Chief Medical Officer, effective immediately. With over 30 years of experience in drug and diagnostic agent development, Dr. Provost's prior roles include leadership positions at GE Healthcare and Pfizer. His extensive background in radiopharmaceuticals and clinical research is expected to enhance Lantheus' strategic vision. President and CEO Mary Anne Heino expressed confidence in Dr. Provost's capabilities to drive the company's innovative solutions aimed at improving patient outcomes.
Lantheus Holdings announced a collaboration with Novartis to include PYLARIFY® (piflufolastat F18) in clinical trials for Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) targeting prostate cancer. This partnership aims to explore how PSMA PET imaging agents can enhance patient access to PSMA-targeted therapies.
The U.S. Total Addressable Market for PSMA PET imaging is now estimated at approximately $1.1 billion, an increase from the previous $220 million, reflecting an additional 30,000 scans per year for metastatic castration-resistant prostate cancer.
Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:30 a.m. ET in Miami, FL. Investors can access a live webcast of the presentation through the Investors section on the company’s website, with a replay available for 30 days afterward. Lantheus provides innovative imaging diagnostics and therapeutics, focusing on serious medical conditions.
Lantheus Holdings, a leader in medical imaging and therapeutics, is set to host its inaugural investor day on May 17, 2022, at 8:00 a.m. in New York City. The event, featuring President and CEO Mary Anne Heino, will cover the company’s prostate cancer and microbubble franchises, along with its overall business strategy. Attendees can expect a PYLARIFY panel discussion and Q&A sessions. In-person attendance is limited and registration will be required. A live webcast will also be available for those unable to attend, ensuring broad access to the event's insights.
Lantheus Holdings (NASDAQ: LNTH) has appointed Ms. Minnie Baylor-Henry, Esq., a prominent regulatory affairs expert, to its Board of Directors. Effective immediately, she will also serve on the Compensation and Science and Technology Committees. Following this appointment, the Board will consist of nine directors, with eight being independent. Brian Markison, Chairman of the Board, highlighted her significant industry experience as essential for the company’s strategy to enhance shareholder value and improve patient outcomes.
Lantheus reported strong financial results for Q4 and FY 2021, with worldwide revenue of $129.6 million and $425.2 million, reflecting increases of 37.6% and 25.3% year-over-year, respectively. However, the company faced a GAAP net loss of $40.2 million for Q4 and $71.3 million for the full year. Adjusted fully diluted EPS improved to $0.25 and $0.49 for Q4 and FY 2021, marking increases of 263.5% and 4.0%. The company anticipates Q1 revenue guidance of $160 million - $170 million and FY 2022 guidance of $685 million - $710 million.
Lantheus Holdings has received FDA approval for its on-site drug manufacturing facility in North Billerica, Massachusetts, designed to produce DEFINITY® (Perflutren Lipid Microsphere), a leading ultrasound enhancing agent. This 16,000 sq. ft. facility aims to enhance supply security and support future growth. The facility will aid in margin expansion as DEFINITY supply becomes integrated from this location. The company intends to ship DEFINITY from this facility immediately, marking an important step in ensuring adequate supply for patients with suboptimal echocardiograms.
Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that data from the OSPREY pivotal trial will be presented at the 2022 ASCO GU Meeting on February 17, 2022, in San Francisco, CA. The presentation will cover the performance of Piflufolastat F 18-PET/CT in prostate cancer patients, specifically analyzing standardized uptake value results based on PSA and Gleason scores. PYLARIFY is highlighted as a PSMA-targeted PET imaging agent for identifying recurrent and metastatic prostate cancer. This data presentation is a key opportunity to showcase Lantheus's advancements in oncology diagnostics.
FAQ
What is the current stock price of Lantheus Holdings (LNTH)?
What is the market cap of Lantheus Holdings (LNTH)?
What does Lantheus Holdings, Inc. specialize in?
What are some key products of Lantheus?
Where is Lantheus Holdings headquartered?
What are the core business units of Lantheus?
Who is the current CEO of Lantheus Holdings?
What recent achievements has Lantheus accomplished?
What financial growth did Lantheus achieve in 2023?
What is the significance of DEFINITY® Vial?
What types of diseases does Lantheus focus on in their diagnostics?
How does Lantheus contribute to precision medicine?
